A Humanized Mouse Model of Astrocytic Pathology in Schizophrenia

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Human evolution has been accompanied by a diversification of astrocytic phenotype and function, that has contributed to species-specific aspects of both human brain function and disease. As such, the development of human astrocytic complexity has paralleled the appearance in evolution of psychiatric disorders unique to humans - the schizophrenias in particular. Yet despite this correlative suggestion that astrocytic pathology might contribute to the disordered thought of schizophrenia, the role of astroglial pathology in its pathogenesis has been difficult to study, in part because of the lack o animal models of human glial pathophysiology. We propose to overcome this limitation, using a new model of human glial-chimeric mouse brains that we have developed, paired with our newly-developed protocols for efficiently and reliably generating astrocytes from patient-derived human induced pluripotential cells (hiPSCs). Using mice neonatally engrafted with glial progenitor cells (GPCs) derived from hiPSCs generated from schizophrenic patients, we will assess the specific contributions of schizophrenic patient-derived astrocytes to disease pathogenesis. In these human glial chimeric mouse brains, the vast majority of resident glia are replaced by human GPC-derived astrocytes and their progenitors, allowing human glial physiology, gene expression, and effects on neural function to be assessed in live adult mice. By pairing this chimerization approach with protocols that we have developed for both generating and purifying GPCs and astrocytes from hiPSCs, and using hiPSC lines produced from patients with juvenile-onset schizophrenia, we will produce mice whose resident glia are largely derived from patients with schizophrenia. In Aim 1, we will assess the relative effects of these schizophrenia-associated astrocytes upon glial syncytial transmission within the cortices of the chimeric mice. In Aim 2, we will next assess the synaptic plasticity of the chimeric mice, as well as the effects of schizophrenia-derived glial chimerization upon their behavioral phenotype and responses to pharmacological stressors. In Aim 3, we will sort engrafted astroglia from the brains into which they have integrated, so as to assess the gene expression patterns of schizophrenic iPSC-derived astrocytes, relative to those of normal hiPSC-derived glia. By means of this multimodal approach, we hope to define the disease-specific effects, gene expression patterns, and paracrine toxicities of schizophrenic hiPSC-derived astrocytes relative to normal hiPSC-derived glia. These diverse lines of investigation should provide us great insight into the species- and cell type-specific roles of human astrocytes in the pathogenesis of schizophrenia. At the same time, by providing a new human glial chimeric model system, new cellular reagents in the form of schizophrenic patient-derived astrocytes, and new gene expression databases covering schizophrenic hiPSC-derived astrocytes, this project should allow us to make available to the field a broad and exciting new set of tools, capabilities and databases. Together, these should greatly accelerate our understanding of human glial dysfunction in the pathogenesis of schizophrenia.